ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

The awards comprise stock options and restricted stock units, with vesting tied to continued employment or service.

Rhea-AI Summary

ORIC Pharmaceuticals (Nasdaq: ORIC) granted equity awards to one new non-executive employee on November 2, 2026, as an inducement to employment.

The awards comprise 14,800 non-qualified stock options and 2,400 restricted stock units under its 2022 Inducement Equity Incentive Plan. The options have an exercise price equal to the stock’s closing price on the grant date. Options vest 25% after one year, with one thirty-sixth of the remaining shares vesting monthly thereafter. Restricted stock units vest one-third on each of the first three grant-date anniversaries. Vesting requires continued employment or service.

Positive

• None.

Negative

• Minor point. Forward-looking: it has not happened yet and may not happen.Equity awards of 14,800 stock options and 2,400 restricted stock units create potential dilution as they vest and options are exercised.

Key Figures

Stock options granted: 14,800 options Restricted stock units granted: 2,400 units Option vesting schedule: 25% after 1 year; 1/36 of remaining shares monthly thereafter +1 more

Stock options granted

14,800 options

Inducement grant to one new non-executive employee

Restricted stock units granted

2,400 units

Inducement grant to one new non-executive employee

Option vesting schedule

25% after 1 year; 1/36 of remaining shares monthly thereafter

Stock options

Restricted stock unit vesting

One-third on each of the first 3 anniversaries

Restricted stock units

Key Terms

non-qualified stock options, restricted stock units, nasdaq rule 5635(c)(4)

3 terms

non-qualified stock options financial

"14,800 non-qualified stock options and 2,400 restricted stock units"

Non-qualified stock options are a type of employee benefit that gives individuals the right to buy company shares at a set price, usually lower than the market value, within a certain period. Unlike other options that may have special tax advantages, these options are taxed as income when exercised, which can affect how much money the employee or investor ultimately gains. They are important because they can influence company compensation strategies and impact the financial outcomes for employees and investors.

restricted stock units financial

"14,800 non-qualified stock options and 2,400 restricted stock units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

nasdaq rule 5635(c)(4) regulatory

"as required by Nasdaq Rule 5635(c)(4)"

NASDAQ Rule 5635(c)(4) is a listing standard that requires a company to obtain shareholder approval before issuing a substantial number of new shares or convertible securities in certain financing or insider-related transactions that would materially dilute existing holders. It matters to investors because the vote gives shareholders a check on deals that could significantly change ownership stakes or voting power—like a homeowners’ association approving a major renovation that affects the whole neighborhood’s value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Nov. 06, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on November 2, 2026 (the “Grant Date”), ORIC granted a total of 14,800 non-qualified stock options and 2,400 restricted stock units to one new non-executive employee who began their employment with ORIC in October 2026.

These inducement grants were granted pursuant to the ORIC Pharmaceuticals, Inc. 2022 Inducement Equity Incentive Plan, subject to recipient’s continued employment or service through each applicable vesting date. The stock options have an exercise price equal to the closing price of ORIC’s common stock on the Grant Date. Twenty-five percent (25%) of the shares subject to the stock options will vest on the one (1) year anniversary of the Grant Date, with one thirty-sixth (1/36^th) of the remaining shares vesting each one-month period thereafter. One-third (1/3^rd) of the restricted stock units will vest on each of the first three anniversaries of the Grant Date. The inducement grants are subject to the terms and conditions of the applicable stock option and restricted stock unit agreements and the ORIC Pharmaceuticals, Inc. 2022 Inducement Equity Incentive Plan.

The inducement grants were approved by ORIC’s Compensation Committee of the Board of Directors, as required by Nasdaq Rule 5635(c)(4), and were granted as a material inducement to employment in accordance with Nasdaq Rule 5635(c)(4).

About ORIC Pharmaceuticals, Inc.

ORIC Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to improving patients’ lives by Overcoming Resistance In Cancer. ORIC’s clinical stage product candidates include (1) rinzimetostat, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and (2) enozertinib, a brain-penetrant inhibitor targeting EGFR atypical and EGFR exon 20 mutations, being developed for NSCLC. ORIC has offices in South San Francisco and San Diego, California. For more information, please go to www.oricpharma.com, and follow us on X or LinkedIn.

Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements as that term is defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, statements regarding the vesting of the inducement grants; target indications for ORIC’s product candidates; the potential advantages of ORIC’s product candidates; and plans underlying ORIC’s clinical trials and development. Words such as “believes,” “anticipates,” “plans,” “expects,” “intends,” “will,” “goal,” “potential” and similar expressions are intended to identify forward-looking statements. The forward-looking statements contained herein are based upon ORIC’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those projected in any forward-looking statements due to numerous risks and uncertainties, including but not limited to: risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics and operating as an early clinical stage company; ORIC’s ability to develop, initiate or complete preclinical studies and clinical trials for, obtain approvals for and commercialize any of its product candidates; changes in ORIC’s plans to develop and commercialize its product candidates; the potential for clinical trials of ORIC’s product candidates to differ from preclinical, initial, interim, preliminary or expected results; negative impacts of health emergencies, economic instability or international conflicts on ORIC’s operations, including clinical trials; the risk of the occurrence of any event, change or other circumstance that could give rise to the termination of ORIC’s license and collaboration agreements; the potential market for our product candidates, and the progress and success of competing therapeutics currently available or in development; ORIC’s ability to raise any additional funding it will need to continue to pursue its business and product development plans; regulatory developments in the United States and foreign countries; ORIC’s reliance on third parties, including contract manufacturers and contract research organizations; ORIC’s ability to obtain and maintain intellectual property protection for its product candidates; the loss of key scientific or management personnel; competition in the industry in which ORIC operates; general economic and market conditions; and other risks. Information regarding the foregoing and additional risks may be found in the section entitled “Risk Factors” in ORIC’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the “SEC”) on August 3, 2026, and ORIC’s future reports to be filed with the SEC. These forward-looking statements are made as of the date of this press release, and ORIC assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law.

Contact:
Dominic Piscitelli, Chief Financial Officer
dominic.piscitelli@oricpharma.com
info@oricpharma.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity inducement awards did ORIC Pharmaceuticals grant on November 2, 2026?

ORIC granted 14,800 non-qualified stock options and 2,400 restricted stock units to one new non-executive employee who began employment in October 2026. The awards were granted under the 2022 Inducement Equity Incentive Plan.

What are the vesting terms for ORIC Pharmaceuticals’ November 2026 inducement grants?

The options vest 25% on the first grant-date anniversary, followed by one thirty-sixth of the remaining shares each month. The restricted stock units vest one-third on each of the first three anniversaries. All vesting is subject to continued employment or service through the applicable vesting date.